Anticoagulation and Antiplatelet Agent Resumption Timing following Traumatic Brain Injury.

Q3 Medicine
Korean Journal of Neurotrauma Pub Date : 2023-09-12 eCollection Date: 2023-09-01 DOI:10.13004/kjnt.2023.19.e42
In-Ho Jung, Jung-Ho Yun, Sung Jin Kim, Jaewoo Chung, Sang Koo Lee
{"title":"Anticoagulation and Antiplatelet Agent Resumption Timing following Traumatic Brain Injury.","authors":"In-Ho Jung,&nbsp;Jung-Ho Yun,&nbsp;Sung Jin Kim,&nbsp;Jaewoo Chung,&nbsp;Sang Koo Lee","doi":"10.13004/kjnt.2023.19.e42","DOIUrl":null,"url":null,"abstract":"<p><p>Traumatic brain injury (TBI) is a major global health concern. Due to the increase in TBI incidence and the aging population, an increasing number of patients with TBI are taking antithrombotic agents for their underlying disease. When TBI occurs in patients with these diseases, there is a conflict between the disease, which requires an antithrombotic effect, and the neurosurgeon, who must minimize intracranial hemorrhage. Nevertheless, there are no clear guidelines for the reversal or resumption of antithrombotic agents when TBI occurs in patients taking antithrombotic agents. In this review article, we intend to classify antithrombotic agents and provide information on them. We also share previous studies on the reversal and resumption of antithrombotic agents in patients with TBI to help neurosurgeons in this dilemma.</p>","PeriodicalId":36879,"journal":{"name":"Korean Journal of Neurotrauma","volume":"19 3","pages":"298-306"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/5b/kjn-19-298.PMC10567523.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Journal of Neurotrauma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13004/kjnt.2023.19.e42","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Traumatic brain injury (TBI) is a major global health concern. Due to the increase in TBI incidence and the aging population, an increasing number of patients with TBI are taking antithrombotic agents for their underlying disease. When TBI occurs in patients with these diseases, there is a conflict between the disease, which requires an antithrombotic effect, and the neurosurgeon, who must minimize intracranial hemorrhage. Nevertheless, there are no clear guidelines for the reversal or resumption of antithrombotic agents when TBI occurs in patients taking antithrombotic agents. In this review article, we intend to classify antithrombotic agents and provide information on them. We also share previous studies on the reversal and resumption of antithrombotic agents in patients with TBI to help neurosurgeons in this dilemma.

Abstract Image

Abstract Image

Abstract Image

颅脑损伤后抗凝和抗血小板药物的恢复时间。
创伤性脑损伤(TBI)是一个主要的全球健康问题。由于TBI发病率的增加和人口的老龄化,越来越多的TBI患者正在为其潜在疾病服用抗血栓药物。当患有这些疾病的患者发生TBI时,需要抗血栓作用的疾病和必须尽量减少颅内出血的神经外科医生之间存在冲突。然而,当服用抗凝血剂的患者出现TBI时,没有明确的抗凝血剂逆转或恢复的指南。在这篇综述文章中,我们打算对抗血栓药物进行分类并提供相关信息。我们还分享了先前关于TBI患者抗血栓药物逆转和恢复的研究,以帮助陷入这种困境的神经外科医生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
41
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信